Download full-text PDF

Source
http://dx.doi.org/10.1007/978-0-387-72293-1_11DOI Listing

Publication Analysis

Top Keywords

shared decision
4
decision making
4
making fertility
4
fertility pediatric
4
pediatric cancers
4
shared
1
making
1
fertility
1
pediatric
1
cancers
1

Similar Publications

Purpose: The priorities and concerns of sarcoidosis patients in the United States (US) have not been well-described.

Methods: A survey constructed by sarcoidosis patients and doctors was administered to US sarcoidosis patients. The survey queried patients concerning their demographics, disease state, disease impact on health and well-being, health care priorities and impressions of sarcoidosis care.

View Article and Find Full Text PDF

[How to report the end-of-life decisions in the clinical record? Proposal of an "ABCD".].

Recenti Prog Med

January 2025

Uoc Anestesia e rianimazione, AO San Camillo-Forlanini, Roma.

Coping with the end of life decision making process in ICU, its complexity adds a challenge for the healthcare team: how to report in the medical record the events and reasoning that led to withholding or withdrawing treatments shifting from intensive to palliative care. Each healthcare team must select the best approach for managing the decision-making process and the necessary rules to ensure a correct clinical history narrative, indicating who must write and what has to be written. Taking into account the team organization, the report may be written not necessarily by the ICU director, but also by a staff physician as a spokesperson in the individual case.

View Article and Find Full Text PDF

Background: Persistent pain is increasingly recognized as a growing issue among adolescents worldwide, with an estimated prevalence of 10-30%. Physical therapy is a recommended treatment modality for managing this kind of pain. Yet, there is still limited knowledge regarding how physiotherapists experience, manage, and follow up this patient population.

View Article and Find Full Text PDF

Biologics approved and in development for atopic dermatitis offer life-changing clinical efficacy with a relatively banal long-term safety profile requiring no laboratory monitoring. Biologic therapies also have their drawbacks, including high payor cost and the need to be administered as every other week subcutaneous injections. Addressing these concerns, studies of longer dosing intervals have been performed in the formal clinical trial setting and during real-world clinical care.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!